Engineered immune cells take aim at blistering skin disease

NCT ID NCT07681388

Recruiting now Disease control Sponsor: Jinbo Chen Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study investigates whether a single infusion of a patient's own genetically modified immune cells (CD19 CAR-T cells) can safely control moderate-to-severe pemphigus vulgaris that hasn't responded to standard treatments. The therapy targets and depletes B cells, which are thought to drive the disease. Three adults with refractory pemphigus vulgaris will receive the treatment after chemotherapy, and researchers will monitor side effects and changes in skin blistering over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD19 CAR-T cells
What this could lead to: If successful, this could offer a new treatment option for people with hard-to-control pemphigus vulgaris, potentially reducing symptoms and need for ongoing medication.
What could go wrong: This is a very early, small study with only 3 participants, so results may not apply broadly. CAR-T therapy carries risks like cytokine release syndrome and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEMPHIGUS VULGARIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pemphigus pemphigus vulgaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PEMPHIGUS VULGARIS

Contacts and locations

Locations

Traditional Chinese and Western Medicine Hospital of Wuhan, Wuhan, Hubei
RECRUITING

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.